IGFBP3 and neoplasm: miR-21 is considered an oncomiR, as its levels increase as tumorigenesis advances, and it downregulates the function of several cellular and molecular pathways by directly targeting genes such as the insulin-like growth factor (IGF)-binding protein-3 (IGFBP3) [58], reversion inducing cysteine-rich protein with kazal motifs (RECK) [59], and TIMP metallopeptidase inhibitor 3 (TIMP3) [59], resulting in enhanced cell migration and invasiveness and reduced apoptosis of tumor cells.